{"id":"eplerenone-night-time","safety":{"commonSideEffects":[{"rate":"5-10","effect":"Hyperkalemia"},{"rate":"3-5","effect":"Dizziness"},{"rate":"2-4","effect":"Fatigue"},{"rate":"1-3","effect":"Abdominal pain"},{"rate":"1-2","effect":"Diarrhea"}]},"_chembl":null,"_fixedAt":"2026-03-30T11:50:41.461627","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Eplerenone selectively inhibits aldosterone binding to mineralocorticoid receptors, preventing aldosterone-mediated sodium reabsorption and potassium excretion in the collecting duct. This leads to increased sodium and water excretion, reduced blood volume and blood pressure, and potassium retention. The night-time dosing formulation is designed to align with circadian patterns of aldosterone secretion and blood pressure regulation.","oneSentence":"Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and other tissues, reducing sodium retention and potassium excretion.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:45:39.730Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Hypertension"},{"name":"Post-myocardial infarction left ventricular dysfunction"}]},"_fixedFields":["pubmed(3)"],"trialDetails":[{"nctId":"NCT00515021","phase":"PHASE4","title":"Diurnal Variation of Plasminogen Activator Inhibitor-1","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2007-04","conditions":"Metabolic Syndrome X","enrollment":21}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"recentPublications":[{"date":"2023 Feb 1","pmid":"36583355","title":"Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes.","journal":"Journal of hypertension"},{"date":"2019 Oct 13","pmid":"31614891","title":"The Effects of Eplerenone on the Circadian Blood Pressure Pattern and Left Ventricular Hypertrophy in Patients with Obstructive Sleep Apnea and Resistant Hypertension-A Randomized, Controlled Trial.","journal":"Journal of clinical medicine"},{"date":"2011 Sep","pmid":"21393354","title":"Efficacy of eplerenone added to renin-angiotensin blockade in elderly hypertensive patients: the Jichi-Eplerenone Treatment (JET) study.","journal":"Journal of the renin-angiotensin-aldosterone system : JRAAS"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Inspra"],"phase":"marketed","status":"active","brandName":"Eplerenone (Night-time)","genericName":"Eplerenone (Night-time)","companyName":"Vanderbilt University Medical Center","companyId":"vanderbilt-university-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and other tissues, reducing sodium retention and potassium excretion. Used for Heart failure with reduced ejection fraction, Hypertension, Post-myocardial infarction left ventricular dysfunction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}